Ratings Dong-A ST Co., Ltd.

Equities

A170900

KR7170900005

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
62,700 ^KRW	+2.96%		-3.09%	-9.26%

May. 22	Dong-A ST to Become Second-Largest Shareholder of Idience in KRW25 Billion Deal	MT
May. 20	Idience Co., Ltd announced that it expects to receive KRW 25.00000052 billion in funding from Dong-A ST Co., Ltd.	CI

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's share price in relation to its net book value makes it look relatively cheap.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Sales forecast by analysts have been recently revised upwards.
For several months, analysts have been revising their EPS estimates roughly upwards.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
DONG-A ST CO., LTD.	-9.26%	389M		-
MERCK KGAA	+16.34%	79.03B		A
KYOWA KIRIN CO. LTD.	+8.65%	8.78B		A-
SK BIOPHARMACEUTICALS CO., LTD.	-16.33%	4.83B		A-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+51.22%	4.65B		-
YUHAN CORPORATION	+2.18%	3.89B		B-
INDIVIOR PLC	+20.51%	2.34B		B
BETTA PHARMACEUTICALS CO., LTD.	-26.79%	2.18B		C-
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+15.12%	2.11B	-	-
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-36.56%	2B		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes